Legend Biotech sets ball rolling on $369m US IPO
Biopharmaceutical company Legend Biotech Corp has kicked off bookbuilding for its Nasdaq IPO of up to $368.5m, according to a source familiar with the matter.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: